Obsessive–compulsive disorder and spectrum across the life span

References

• Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56(Suppl 4)3–6
   PubMed Web of Science ®Google Scholar
• Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA. Obsessive-compulsive and spectrum disorders: Overview and quality of life issues. J Clin Psychiatry 1996; 57(Suppl 8)3–6
   PubMedGoogle Scholar
• Eisen JL, Rasmussen SA. Obsessive-compulsive disorder with psychotic features. J Clin Psychiatry 1993; 54: 373–379
   PubMed Web of Science ®Google Scholar
• Kozac MJ, Foa EB. Obsessions overvalued ideas, and delusions in obsessive compulsive disorder. Behav Res Ther 1994; 32: 343–353
   Google Scholar
• Foa EB, Kozak MJ, Goodman WK, et al. DSM-IV field trial: Obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 90–96
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnositic and statistical manual of mental disorders ( 4th edn, DSM IV,. 1994), Washington DC: American Psychiatric Association.
   Google Scholar
• Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992; 49: 21–28
   PubMed Web of Science ®Google Scholar
• Simansky KJ, Dave KD, Inemer BR, Nicklous DM, Padron JM, Aloyo VJ, Romano AG. A 5-HT2C agonist elicits hyperactivity and oral dyskinesia with hypophagia in rabbits. Physiol Behav 2004; 82: 97–107
   Google Scholar
• Hollander E, Prohovnik I, Stein D. Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1995; 7: 485–490
   PubMedGoogle Scholar
• Mundo E, Rouillon F, Figuera ML, Stigler M. Fluvoxamine in obsessive-compulsive disorder: Similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001; 16: 461–468
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577–585
   PubMed Web of Science ®Google Scholar
• Jeffreys DE, Castle DJ. Body dysmorphic disorder – A fear of imagined ugliness. Aust Fam Phys 2003; 32: 722–725
   Google Scholar
• Phillips KA, McElroy SL, Keck PE, Jr, Hudson JI, Pope HG, Jr. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull 1994; 30: 179–186
   PubMedGoogle Scholar
• Fukuda O. Statistical analysis of dysmorphophobia in out-patient clinic. Jpn J Plast Reconstruct Surg 1977; 20: 569–577
   Google Scholar
• Coterill JA. Body dysmorphic disorder. Dermatol Clin 1996; 14: 457–463
   Google Scholar
• Hollander E, Wong CM. Body dysmorphic disorder, pathological gambling, and sexual compulsion. J Clin Psychiatry 1995; 56(Suppl 4)7–12
   PubMedGoogle Scholar
• Hollander E, Cohen LJ, Simeon D. Body dysmorphic disorder. Psychiatr Ann 1993; 23: 359–364
   Web of Science ®Google Scholar
• Phillips KA. Body dysmorphic disorder: diagnosis and treatment of imagined ugliness. J Clin Psychiatry 1996; 57(Suppl 8)61–64
   PubMedGoogle Scholar
• Phillips KA, McElroy SL, Hudosn JL, Pope HG, Jr. Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both?. J Clin Psychiatry 1995; 56(Suppl 4)41–51
   PubMedGoogle Scholar
• Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094–1099
   PubMed Web of Science ®Google Scholar
• Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999; 56: 1033–1039
   PubMed Web of Science ®Google Scholar
• Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998; 59: 165–171
   PubMed Web of Science ®Google Scholar
• Hollander E, Buchalter AJ, De Caria CM. Pathological gambling. Psychiatr Clin North Am 2000; 23: 629–642
   PubMed Web of Science ®Google Scholar
• Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalance of disordered gambling behaviour in the United States and Canada: A research analysis. Am J Public Health 1999; 89: 1369–1376
   PubMed Web of Science ®Google Scholar
• Shaffer HJ. Estimating the prevalence of adolescent gambling: a quantitative synthesis and guide toward standard gambling nomenclature. J Gambling Stud 1996; 12: 193–214
   PubMedGoogle Scholar
• Korn DA, Shaffer HJ. Gambling and the health of the public: Adopting a public health perspective. J Gamb Stud 1999; 15: 289–365
   PubMedGoogle Scholar
• Winstanley CA, Theobald DEH, Dalley JW, Glennon JC, Robbins TW. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5HT depletion. Psychopharmacology 2004; 176: 376–385
   PubMedGoogle Scholar
• Winstanley CA, Dalley JW, Theobald DEH, Robbins TW. Fractionating impulsivity: Contrasting effects of central 5-HT depletion on different measures of impulsive behaviour. Neuropsychopharmacology 2004; 29: 1331–1343
   PubMed Web of Science ®Google Scholar
• Hollander, E, Pallanti, S, Baldini-Rossi, N, Sood, E, Buchsbaum, M. Sustained release lithium/placebo treatment response and FDG-PET imaging of wagering in bipolar spectrum pathological gamblers. Scientific Abstract. 40th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December, 9–13, 2001.
   Google Scholar
• Hollander E, DeCaria CM, Mari E, Wong CM, Mosovich S, Grossman R, Begaz T. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 1998; 155: 1781–1783
   PubMed Web of Science ®Google Scholar
• Hollander, E, Pallanti, S, Baldini-Rossi, N, Sood, E. Sustained release lithium/placebo treatment response in bipolar spectrum pathological gamblers. Poster presented at the 42nd Annual New Clinical Drug Evaluation Unit Meeting, Boca RatonFL, 2002.
   Google Scholar
• Jamain S, Betancur C, Giros B, Leboyer M, Bourgeron T. Genetics of autism: from genome scans to candidate genes. Med Sci (Paris) 2003; 19: 1081–1090
   Google Scholar
• Hollander E, King A, Delaney K, Smith CJ, Silverman JM. Obsessive compulsive behaviors in parents of multiplex autism families. Psychiatr Res 2003; 177: 11–16
   Google Scholar